Literature DB >> 23857540

Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression.

Andrew H Miller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23857540      PMCID： PMC3717552          DOI： 10.1038/npp.2013.140

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

Review 1.  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Authors:  Gerard Sanacora; Giulia Treccani; Maurizio Popoli
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 2.  Signaling pathways underlying the rapid antidepressant actions of ketamine.

Authors:  Ronald S Duman; Nanxin Li; Rong-Jian Liu; Vanja Duric; George Aghajanian
Journal:  Neuropharmacology       Date:  2011-09-02       Impact factor: 5.250

Review 3.  Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.

Authors:  Andrew H Miller; Vladimir Maletic; Charles L Raison
Journal:  Biol Psychiatry       Date:  2009-01-15       Impact factor: 13.382

4.  NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice.

Authors:  Adam K Walker; David P Budac; Stephanie Bisulco; Anna W Lee; Robin A Smith; Brent Beenders; Keith W Kelley; Robert Dantzer
Journal:  Neuropsychopharmacology       Date:  2013-03-19       Impact factor: 7.853

5.  Connecting inflammation with glutamate agonism in suicidality.

Authors:  Sophie Erhardt; Chai K Lim; Klas R Linderholm; Shorena Janelidze; Daniel Lindqvist; Martin Samuelsson; Kristina Lundberg; Teodor T Postolache; Lil Träskman-Bendz; Gilles J Guillemin; Lena Brundin
Journal:  Neuropsychopharmacology       Date:  2012-12-03       Impact factor: 7.853

6.  Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?

Authors:  Johann Steiner; Martin Walter; Tomasz Gos; Gilles J Guillemin; Hans-Gert Bernstein; Zoltán Sarnyai; Christian Mawrin; Ralf Brisch; Hendrik Bielau; Louise Meyer zu Schwabedissen; Bernhard Bogerts; Aye-Mu Myint
Journal:  J Neuroinflammation       Date:  2011-08-10       Impact factor: 8.322
  6 in total
  33 in total

1.  What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?

Authors:  Ian Davis; Aimin Liu
Journal:  Expert Rev Neurother       Date:  2015-05-24       Impact factor: 4.618

2.  Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.

Authors:  Sara Costi; Nicholas T Van Dam; James W Murrough
Journal:  Curr Behav Neurosci Rep       Date:  2015-10-01

3.  Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study.

Authors:  Jennifer L Kruse; Joshua Hyong-Jin Cho; Richard Olmstead; Lin Hwang; Kym Faull; Naomi I Eisenberger; Michael R Irwin
Journal:  Psychoneuroendocrinology       Date:  2019-07-03       Impact factor: 4.905

4.  Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Authors:  Ruin Moaddel; Michelle Shardell; Mohammed Khadeer; Jacqueline Lovett; Bashkim Kadriu; Sarangan Ravichandran; Patrick J Morris; Peixiong Yuan; Craig J Thomas; Todd D Gould; Luigi Ferrucci; Carlos A Zarate
Journal:  Psychopharmacology (Berl)       Date:  2018-08-16       Impact factor: 4.530

Review 5.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 6.  Involvement of extrasynaptic glutamate in physiological and pathophysiological changes of neuronal excitability.

Authors:  Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2018-05-15       Impact factor: 9.261

Review 7.  Multistage drug effects of ketamine in the treatment of major depression.

Authors:  Martin Walter; Shijia Li; Liliana Ramona Demenescu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-13       Impact factor: 5.270

8.  Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.

Authors:  Timothy B Meier; Wayne C Drevets; Brent E Wurfel; Bart N Ford; Harvey M Morris; Teresa A Victor; Jerzy Bodurka; T Kent Teague; Robert Dantzer; Jonathan Savitz
Journal:  Brain Behav Immun       Date:  2015-11-04       Impact factor: 7.217

9.  Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.

Authors:  Jonathan Savitz; Wayne C Drevets; Chelsey M Smith; Teresa A Victor; Brent E Wurfel; Patrick S F Bellgowan; Jerzy Bodurka; T Kent Teague; Robert Dantzer
Journal:  Neuropsychopharmacology       Date:  2014-07-30       Impact factor: 7.853

10.  A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression.

Authors:  Lawrence T Park; Bashkim Kadriu; Todd D Gould; Panos Zanos; Deanna Greenstein; Jennifer W Evans; Peixiong Yuan; Cristan A Farmer; Mark Oppenheimer; Jomy M George; Lilian W Adeojo; H Ralph Snodgrass; Mark A Smith; Ioline D Henter; Rodrigo Machado-Vieira; Andrew J Mannes; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2020-07-29       Impact factor: 5.176
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.